Trial Profile
A study evaluating drug drug interactions due to ritonavir in hepatitis C patients treated with Ombitasvir/Paritaprevir/ritonavir ± Dasabuvir ± Ribavirin regimen.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 08 Jul 2017 New trial record